150
Participants
Start Date
November 20, 2013
Primary Completion Date
May 13, 2016
Study Completion Date
November 5, 2020
ASP0113
intramuscular injection
Placebo
intramuscular injection
Site AU61001, Adelaide SA
Site ES34001, Barcelona
Site DE49002, Berlin
Site US10012, The Bronx
Site DE49001, Berlin
Site US10045, Buffalo
Site US10042, Pittsburgh
Site DE49005, Hamburg
Site US10038, Charlottesville
Site US10031, Richmond
Site US10050, Greenville
Site US10047, Charleston
Site US10058, Atlanta
Site US10013, Atlanta
Site FR33005, Bordeaux
Site FR33003, Montpellier
Site US10027, Nashville
Site US10046, Lexington
Site FR33004, Nantes
Site US10001, Cleveland
Site US10057, Indianapolis
Site US10048, Detroit
Site ES34004, Zaragoza
Site DE49008, Bonn
Site US10029, Madison
Site US10030, Chicago
Site US10009, Chicago
Site US10016, St Louis
Site FR33001, Nice
Site US10015, Omaha
Site US10041, New Orleans
Site US10028, Houston
Site US10044, Aurora
Site US10014, Salt Lake City
Site US10026, Phoenix
Site US10003, Los Angeles
Site DE49003, Erlangen
Site US10004, San Diego
Site US10036, San Francisco
Site US10037, San Francisco
Site US10020, Seattle
Site US10018, New Haven
Site US10049, Portland
Site US10023, Ann Arbor
Site US10011, Seattle
Site AU61002, Sydney
Site AU61004, Woolloongabba
Site CA15004, Vancouver
Site CA15003, Halifax
Site CA15005, London
Site CA15006, Toronto
Site ES34003, Barcelona
Site ES34002, Barcelona
Collaborators (1)
Vical
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY